logo

Biotechnology & Drugs News

Share

Merck Discontinues Development Of MK-7110 For Treatment Of Hospitalized Patients With COVID-19

Merck, Ridgeback Biotherapeutics Provide Update On Clinical Development Program For Molnupiravir

Oxford BioMedica FY Total Revenues Up 37% To £87.7 Mln

Verizon: Hyper Precise Location Now Available In 100+ U.S. Markets